• Explore /
  • Poster
  • / Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with <em>FGFR </em>mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).

Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).

Abstract Poster

Authors

null

Arlene O. Siefker-Radtke

UT MD Anderson Cancer Center, Houston, TX

Arlene O. Siefker-Radtke , Andrea Necchi , Eli Rosenbaum , Stephane Culine , Earle Frederick Burgess , Peter H. O'Donnell , Scott T. Tagawa , Yousef Zakharia , Anne OHagan , Anjali Narayan Avadhani , Bob Zhong , Ademi E. Santiago-Walker , Tito Roccia , Yohann Loriot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02365597

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 450)

DOI

10.1200/JCO.2018.36.6_suppl.450

Abstract #

450

Poster Bd #

G21

Abstract Disclosures

Similar Posters

First Author: Antoine Italiano

First Author: Matt D. Galsky

First Author: David A. Reardon

First Author: Panpan Zhang